Response to Nivolumab as Salvage Therapy in a Patient with Thymic Carcinoma
Journal
Journal of Thoracic Oncology
Journal Volume
13
Journal Issue
3
Pages
e36-e39
Date Issued
2018
Author(s)
SDGs
Other Subjects
cisplatin; cyclophosphamide; doxorubicin; fluorouracil; folinic acid; gemcitabine; mismatch repair protein PMS2; MutL protein homolog 1; nivolumab; paclitaxel; programmed death 1 ligand 1; protein MSH6; tumor marker; monoclonal antibody; nivolumab; pembrolizumab; adult; cancer chemotherapy; cancer palliative therapy; cancer radiotherapy; cancer staging; case report; clinical article; computer assisted tomography; dyspnea; female; heart metastasis; hemoptysis; human; human cell; human tissue; immunohistochemistry; Letter; liver metastasis; lung gas exchange; lung hilus; lung metastasis; lymph node metastasis; lymphadenopathy; mediastinum metastasis; middle aged; multiple cycle treatment; pleura metastasis; priority journal; protein expression; repeated drug dose; salvage therapy; supraclavicular lymph node; thymus cancer; treatment response; lung tumor; salvage therapy; thymoma; tumor recurrence; Antibodies, Monoclonal, Humanized; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Salvage Therapy; Thymoma
Publisher
Elsevier Inc
Type
letter